Addex

Allosteric modulators for human health

  • About us
    • Overview
    • Addex Corporate Presentation
    • Our people
      • Executive Officers
      • Non-Executive Directors
      • Scientific Advisory Board
    • Contact
    • Privacy Policy
    • Careers
  • Pipeline
    • Research And Development
      • mGlu2 NAM Developing a Novel Approach to Fight Mild Neurocognitive Disorders and Depression
    • Clinical and Pre-Clinical Pipeline
  • Technology platform
    • Allosteric modulation
    • Our capabilities
      • Screening Assays
      • Chemistry
    • Publications
  • Partners & collaboration
  • Investors
    • Stock Data
    • Addex Corporate Presentation
    • Press releases
    • Ad hoc announcements (Art. 53 L.R)
    • Events
    • Financial Reports
    • Analyst Reports
    • General Meetings
    • SEC / SIX Filings
    • Guide to US ADSS for Six Shareholders
    • Register for email news
    • Corporate Governance
    • Contact
  • Media
    • Press releases
    • Contact
about us

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

 

 

 

Research And Development

   

 

Publications
  • Dipraglurant-IR for PD-LID
  • Dipraglurant-ER for dystonia (BLEPHAROSPASM)
  • ADX71149 for epilepsy
  • GABAB PAM for the treatment of substance use disorder
  • GABAB PAM for CMT1A
  • mGlu7 NAM for PTSD
  • mGlu2 NAM for mild neurocognitive disorders
  • M4 PAM for Schizophrenia & Other Psychosis
  • mGlu4 PAM for Parkinson’s disease
  • mGlu3 PAM for neurodegenerative disorders
Placeholder image

Technology platform

Allosteric Modulation

Read more
Placeholder image

Partners & Collaborations

Industry

Read more

Latest news Latest news icon

  • 05.19
    2022

    Addex Announces Participation in the H.C. Wainwright Global Investment Conference

  • 05.13
    2022

    Addex Announces Participation in the 22nd Bio€quity Europe Conference

  • 05.10
    2022

    Addex Shareholders Approve All Resolutions at Annual General Meeting

  • 05.05
    2022

    Addex Reports Q1 2022 Financial Results

  • 04.28
    2022

    Addex to Present at the Swiss Biotech Day 2022

Contact us

If you have any questions please let me know
  • Contact form
2022 © Addex therapeutics